Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases
- 1 January 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 70 (1) , 18-26
Abstract
Objectives: Many studies of disease state mechanisms reveal that unbridled inflammation is to blame for many of the symptoms associated with autoimmune diseases such as Crohn’s and Rheumatoid Arthritis (RA). While therapies aimed at decreasing levels of pro-inflammatory cytokines exist, some have failed clinically or have extensive adverse effects. The aim of this review is to discuss common drug targets for anti-inflammatory therapies as well as explore potential mechanisms of action for new therapies. Various studies done on novel mechanisms targeting pro-inflammatory cytokine release as well as leukocyte chemotaxis have been researched for discussion here. Both of these contribute to tissue injury and patient symptoms in inflammatory and autoimmune disease states. Key findings: While many current drug targets suppress inflammation via the receptor, research aimed at identifying new compounds and signaling mechanisms is ongoing to identify new targets within pro-inflammatory signaling pathways, or specific immune cell types. Conclusions: While glucocorticoids and monoclonal antibodies have shown to be efficacious, some patients have encountered mixed results. Biologic therapies also come with a high price tag Thus, novel compounds with new immune drug targets are ideal for patients whose therapies have not been successful.Keywords
This publication has 55 references indexed in Scilit:
- Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stressJournal of Neuroinflammation, 2014
- Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblastsAnnals of the Rheumatic Diseases, 2013
- Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) InhibitorsPLOS ONE, 2013
- Restoration of Corticosteroid Sensitivity by p38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe AsthmaPLOS ONE, 2012
- The Tumor Necrosis Factor Superfamily of Cytokines in the Inflammatory Myopathies: Potential Targets for TherapyJournal of Immunology Research, 2011
- Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid ArthritisPLOS ONE, 2011
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- Tumor necrosis factor signalingCell Death & Differentiation, 2003